Persistence with bisphosphonate treatment and fracture risk in a managed care setting

被引：0
|
作者：
Cosman, F
Gold, DT
Frytak, J
Baran, RW
Amonkar, MM
Martin, B
机构：
[1] Helen Hayes Hosp, W Haverstraw, NY USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] i3 Magnifi, Eden Prairie, MN USA
[4] Roche Biomed Labs, Nutley, NJ USA
[5] GSK, Collegeville, PA USA
[6] Univ Arkansas, Little Rock, AR 72204 USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2005年 / 12卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：795 / 795
页数：1
相关论文
共 50 条
  • [31] Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting
    Simpson, Ross J., Jr.
    Tunceli, Kaan
    Ramey, Dena R.
    Neff, David R.
    Kern, David M.
    Hsieh, Hui-Min
    Wertz, Debra A.
    Stephenson, Judith J.
    Marrett, Elizabeth
    Tomassini, Joanne E.
    Jacobson, Terry A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (05) : 399 - 407
  • [32] Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women
    Izano, Monika A.
    Lo, Joan C.
    Adams, Annette L.
    Ettinger, Bruce
    Ott, Susan M.
    Chandra, Malini
    Hui, Rita L.
    Niu, Fang
    Li, Bonnie H.
    Neugebauer, Romain S.
    JAMA NETWORK OPEN, 2020, 3 (12) : E2025190
  • [33] Modeling the contribution of long-term persistence with weekly or yearly bisphosphonate treatment to fracture outcomes.
    Rietbrock, S.
    Olson, M.
    van Staa, T.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S130 - S130
  • [34] Dermatologic formularies in the managed care setting
    James, WD
    ARCHIVES OF DERMATOLOGY, 1996, 132 (09) : 1120 - 1121
  • [35] Bisphosphonate use after clinical fracture and risk of new fracture
    J. Bergman
    A. Nordström
    P. Nordström
    Osteoporosis International, 2018, 29 : 937 - 945
  • [36] Bisphosphonate use after clinical fracture and risk of new fracture
    Bergman, J.
    Nordstrom, A.
    Nordstrom, P.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (04) : 937 - 945
  • [37] Persistence and compliance with omalizumab in a managed care population
    Gutierrez, B.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S160 - S160
  • [38] Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting
    LaFleur, J.
    McAdam-Marx, C.
    Ascher, C. V.
    Alder, S.
    Sheng, X.
    Brixner, D. I.
    Silverman, S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S435 - S435
  • [39] Statin therapy persistence in a managed care population
    Wang, SM
    Yang, W
    Nichol, MB
    Dow, T
    Johnson, KA
    VALUE IN HEALTH, 2006, 9 (03) : A133 - A134
  • [40] Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study
    van Geel, Tineke A. C. M.
    Bliuc, Dana
    Geusens, Piet P. M.
    Center, Jacqueline R.
    Dinant, Geert-Jan
    Thach Tran
    van den Bergh, Joop P. W.
    McLellan, Alastair R.
    Eisman, John A.
    PLOS ONE, 2018, 13 (06):
12345